← Eichor
Condition: Allogeneic Hematopoietic Cell Transplant Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Allogeneic Hematopoietic Cell Transplant

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hemato
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07235501Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation
NA · 1 location(s) · Dana-Farber Cancer Institute · NCT05335434Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administ
Phase 1/Phase 2 · 8 location(s) · SNIPR Biome Aps. · NCT06938867A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Ce
Phase 1 · 21 location(s) · TScan Therapeutics, Inc. · NCT05473910Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
NA · 1 location(s) · Peking University People's Hospital · NCT07588594CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure
NA · 1 location(s) · NYU Langone Health · NCT06569082Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT
NA · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06241274MRD Response-adapted Allo-HSCT for Adverse-risk AML
NA · 1 location(s) · Peking University People's Hospital · NCT06301425Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treat
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06769191The HOPE Biobank Resource (BMT CTN 2402 HOPE)
Phase N/A · 6 location(s) · Medical College of Wisconsin · NCT07227155Oral, Chemosensory and Trigeminal Functions in Allo-HSCT
Phase N/A · 1 location(s) · University of Oslo · NCT06003660Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07500441Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
Phase 4 · 1 location(s) · Chinese PLA General Hospital · NCT07101588AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation
NA · 1 location(s) · Rigshospitalet, Denmark · NCT06281496Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infec
Phase 1/Phase 2 · 1 location(s) · LucasBio · NCT07670468Momelotinib During and After HCT in Myelofibrosis
Phase 1 · 1 location(s) · Massachusetts General Hospital · NCT07104799Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Phase 1 · 1 location(s) · Stanford University · NCT06551584Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Phase 2 · 1 location(s) · Loyola University · NCT05554068Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Foll
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05470491Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignanc
NA · 1 location(s) · Fred Hutchinson Cancer Center · NCT04829136Vitamin A and D Supplementation in Allogeneic HCT
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT06508099CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
Phase 1/Phase 2 · 1 location(s) · Zhejiang University · NCT05827835Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Vir
Phase 4 · 1 location(s) · Beijing Children's Hospital · NCT07029958A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT
Phase 2 · 1 location(s) · WeiShi · NCT07606703Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation
EARLY_Phase 1 · 1 location(s) · Case Comprehensive Cancer Center · NCT04332341Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Chil
NA · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT07693881Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versu
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06996119Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
Phase 2 · 1 location(s) · University of California, Irvine · NCT06028828Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus H
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07366801Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.